title: Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease: A 'Real World' Clinical Perspective.
abstract: The introduction of collagenase Clostridium histolyticum (CCH) as a treatment option for Peyronie's disease (PD), defined as the abnormal formation of collagen on the tunica albuginea of the penis, has provided patients with a promising new conservative therapy. Studies have shown that CCH improves curvature by an average of 17°, and although patient and sexual partner satisfaction is high, the improvement has arguable clinical implications. Similarly, the efficacy and cost of CCH contrasts strongly with more invasive surgical management, and is further limited by rare, but serious, complications and several contraindications. The future of CCH involves well-designed trials analyzing the effects of CCH on patients who are currently not indicated for therapy, and the optimal amount of treatment for the most efficient treatment possible. CCH provides a promising treatment option for patients who do not desire invasive management, but need further trials to fully elucidate its treatment implications.
authors: Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA.
authors: James
authors: J
authors: Anaissie
authors: Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA.
authors: Wayne J G
authors: WJ
authors: Hellstrom
authors: Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA. faysalyafi@gmail.com.|Department of Urology, UC Irvine Medical Center, 333 The City Blvd. W, Suite 2100, Orange, CA, USA. faysalyafi@gmail.com.
authors: Faysal A
authors: FA
authors: Yafi
mesh_terms: D047009:Hathewaya histolytica / Q000737:chemistry*; D006801:Humans; D008297:Male; D003012:Microbial Collagenase / Q000008:administration & dosage* / Q000737:chemistry; D010411:Penile Induration / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D003012:Microbial Collagenase